[Effect of low doses of folic acid on selected biochemical atherosclerosis risk factors--preliminary study].
The aim of the present paper was evaluation of the impact of the three-months' supplementation with low doses of folic acid on concentration of homocysteine and other biochemical atherosclerosis risk factors with patients endangered with ischemic stroke or other disease being atherosclerosis-derivative.


METHODS
The examined group consisted of 34 adult children of parents of which at least one fell ill at a young age with ischemic stroke. There were examined 9 men and 25 women aged from 19 to 36 years (average age 24.8 years). The testing procedure consisted in three-months' supplementation with folic acid (a 0.4 mg a day) and in check-up of blood parameters. The tests were performed prior to and after 3 months of taking folic acid. There were following laboratory tests performed: lipid profile [triglycerides, total cholesterol as well as LDL-cholesterol and HDL-cholesterol fractions, apolipoprotein B and Al, lipoprotein(a)] and folic acid, homocysteine, fibrinogen, von Willebrand factor as well as blood cell count, thrombocytes, ESR and basic biochemical parameters.


RESULTS
Increased average concentration levels were detected for folic acid by 5.4 ng/dl (increase by 62.8%), apolipoprotein Al by 2.3 mg/dl (1.5%) and for fibrinogen by 0.2 g/l (7.1%). Decreased average concentration levels were detected for: homocysteine by 2.1 micromol/ l (drop by 18.9%) and for LDL-cholesterol by 4.4 mg/dl (4.4%/1). Furthermore, a significant increase in average concentration level of uric acid was detected as well as drop in average hemoglobin value, erythrocytes, creatinine and urea. Other blood cell count elements, thrombocytes, ESR and biochemical parameters did not show, in a check test, any significant differences.


CONCLUSIONS
Low doses of folic acid, owing to its reducing influence on some risk factors, may be recommended with precautions in the atherosclerosis prevention, e.g. for families with past premature cardiovascular episode. However, insufficient number of tested persons does not permit to draw more radical conclusions. The tests should be conducted on a bigger group of patients.
Mierzecki
Artur
A
Pomorska Akademia Medyczna w Szczecinie, Samodzielna Pracownia Kształcenia Lekarza Rodzinnego, kierownik: dr med. A. Mierzecki; roklr@sci.pam.szczecin.pl
Bukowska
Hanna
H
Honczarenko
Krystyna
K
Jastrzebska
Maria
M
Naruszewicz
Marek
M
D000328:Adult; D016632:Apolipoprotein A-I / Q000097:blood; D050197:Atherosclerosis / Q000188:drug therapy / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005492:Folic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D006397:Hematinics / Q000494:pharmacology; D006710:Homocysteine / Q000097:blood / Q000187:drug effects*; D006801:Humans; D008297:Male; D012307:Risk Factors; D013997:Time Factors
D016632:Apolipoprotein A-I; D008078:Cholesterol, LDL; D006397:Hematinics; D006710:Homocysteine; D005340:Fibrinogen; D005492:Folic Acid